AAPL335.92-1.10 (-0.33%) ▼|ABBV265.12+0.04 (+0.02%) ▲|ABT101.07-2.42 (-2.34%) ▼|ACN177.41-6.11 (-3.33%) ▼|ADBE238.93-1.76 (-0.73%) ▼|AMAT474.25-0.13 (-0.03%) ▼|AMD629.26+14.65 (+2.38%) ▲|AMGN406.04-0.05 (-0.01%) ▼|AMT167.26-3.52 (-2.06%) ▼|AMZN249.38+0.11 (+0.04%) ▲|AVGO350.36-4.63 (-1.30%) ▼|AXP305.66+3.70 (+1.23%) ▲|BA196.80-3.13 (-1.57%) ▼|BAC56.03+0.03 (+0.05%) ▲|BKNG157.41+1.51 (+0.97%) ▲|BLK1,073.45+12.56 (+1.18%) ▲|BMY61.50+0.35 (+0.57%) ▲|BNY150.19+0.68 (+0.45%) ▲|BRK-B505.18-1.99 (-0.39%) ▼|C132.10+0.17 (+0.13%) ▲|CAT805.25-6.77 (-0.83%) ▼|CL85.32-0.61 (-0.71%) ▼|CMCSA22.13-0.42 (-1.86%) ▼|COF196.61+0.51 (+0.26%) ▲|COP129.34+1.25 (+0.98%) ▲|COST896.48-8.22 (-0.91%) ▼|CRM238.22+0.64 (+0.27%) ▲|CSCO106.97+0.54 (+0.51%) ▲|CVS85.05-0.81 (-0.94%) ▼|CVX205.65+0.14 (+0.07%) ▲|DE694.94-14.54 (-2.05%) ▼|DHR223.77+2.21 (+1.00%) ▲|DIS105.56+2.10 (+2.03%) ▲|DUK113.23-0.94 (-0.82%) ▼|EMR156.14+1.55 (+1.00%) ▲|FDX279.54-11.96 (-4.10%) ▼|GD336.29-7.04 (-2.05%) ▼|GE319.78-0.02 (-0.01%) ▼|GEV955.04+3.22 (+0.34%) ▲|GILD149.69-1.68 (-1.11%) ▼|GM80.57-3.20 (-3.82%) ▼|GOOG339.01+4.03 (+1.20%) ▲|GOOGL342.36+4.53 (+1.34%) ▲|GS923.29-13.07 (-1.40%) ▼|HD292.18-4.54 (-1.53%) ▼|HON211.79-0.78 (-0.37%) ▼|IBM227.06-5.70 (-2.45%) ▼|INTC127.39+4.79 (+3.91%) ▲|INTU277.13-9.67 (-3.37%) ▼|ISRG399.52+1.22 (+0.31%) ▲|JNJ270.68+1.51 (+0.56%) ▲|JPM338.56+1.03 (+0.31%) ▲|KO88.10+0.01 (+0.01%) ▲|LIN468.14-1.58 (-0.34%) ▼|LLY1,181.89+30.90 (+2.68%) ▲|LMT523.70-0.98 (-0.19%) ▼|LOW188.49-2.87 (-1.50%) ▼|LRCX307.16-0.12 (-0.04%) ▼|MA566.08+6.16 (+1.10%) ▲|MCD237.02-1.30 (-0.55%) ▼|MDLZ60.86-0.58 (-0.94%) ▼|MDT88.51-0.79 (-0.88%) ▼|META777.59+33.49 (+4.50%) ▲|MMM167.52-2.78 (-1.63%) ▼|MO68.88-0.07 (-0.10%) ▼|MRK147.98-0.10 (-0.07%) ▼|MS196.32-2.07 (-1.04%) ▼|MSFT497.93-2.66 (-0.53%) ▼|MU1,080.53+8.65 (+0.81%) ▲|NEE75.62-1.40 (-1.82%) ▼|NFLX71.72+0.36 (+0.50%) ▲|NKE35.99-0.06 (-0.17%) ▼|NOW137.78-3.00 (-2.13%) ▼|NVDA224.58-0.93 (-0.41%) ▼|ORCL139.54-5.02 (-3.47%) ▼|PEP128.15-2.03 (-1.56%) ▼|PFE28.41+0.23 (+0.82%) ▲|PG145.68-1.71 (-1.16%) ▼|PLTR192.59+0.80 (+0.42%) ▲|PM191.50+0.66 (+0.35%) ▲|QCOM194.26-2.98 (-1.51%) ▼|RTX188.61-3.58 (-1.86%) ▼|SBUX93.65-0.49 (-0.52%) ▼|SCHW99.49-0.01 (-0.01%) ▼|SO82.89-0.58 (-0.69%) ▼|SPG204.70+0.54 (+0.26%) ▲|T25.45+0.15 (+0.59%) ▲|TMO678.39+13.09 (+1.97%) ▲|TMUS165.35-0.31 (-0.19%) ▼|TSLA377.94-2.18 (-0.57%) ▼|TXN270.65-1.97 (-0.72%) ▼|UBER69.22-0.20 (-0.29%) ▼|UNH375.01+3.72 (+1.00%) ▲|UNP274.07-1.46 (-0.53%) ▼|UPS92.05-3.77 (-3.93%) ▼|USB58.40-0.08 (-0.14%) ▼|V367.98+6.46 (+1.79%) ▲|VZ47.32+0.80 (+1.72%) ▲|WFC82.18+0.28 (+0.34%) ▲|WMT107.59-2.94 (-2.66%) ▼|XOM162.14+0.91 (+0.56%) ▲|AAPL335.92-1.10 (-0.33%) ▼|ABBV265.12+0.04 (+0.02%) ▲|ABT101.07-2.42 (-2.34%) ▼|ACN177.41-6.11 (-3.33%) ▼|ADBE238.93-1.76 (-0.73%) ▼|AMAT474.25-0.13 (-0.03%) ▼|AMD629.26+14.65 (+2.38%) ▲|AMGN406.04-0.05 (-0.01%) ▼|AMT167.26-3.52 (-2.06%) ▼|AMZN249.38+0.11 (+0.04%) ▲|AVGO350.36-4.63 (-1.30%) ▼|AXP305.66+3.70 (+1.23%) ▲|BA196.80-3.13 (-1.57%) ▼|BAC56.03+0.03 (+0.05%) ▲|BKNG157.41+1.51 (+0.97%) ▲|BLK1,073.45+12.56 (+1.18%) ▲|BMY61.50+0.35 (+0.57%) ▲|BNY150.19+0.68 (+0.45%) ▲|BRK-B505.18-1.99 (-0.39%) ▼|C132.10+0.17 (+0.13%) ▲|CAT805.25-6.77 (-0.83%) ▼|CL85.32-0.61 (-0.71%) ▼|CMCSA22.13-0.42 (-1.86%) ▼|COF196.61+0.51 (+0.26%) ▲|COP129.34+1.25 (+0.98%) ▲|COST896.48-8.22 (-0.91%) ▼|CRM238.22+0.64 (+0.27%) ▲|CSCO106.97+0.54 (+0.51%) ▲|CVS85.05-0.81 (-0.94%) ▼|CVX205.65+0.14 (+0.07%) ▲|DE694.94-14.54 (-2.05%) ▼|DHR223.77+2.21 (+1.00%) ▲|DIS105.56+2.10 (+2.03%) ▲|DUK113.23-0.94 (-0.82%) ▼|EMR156.14+1.55 (+1.00%) ▲|FDX279.54-11.96 (-4.10%) ▼|GD336.29-7.04 (-2.05%) ▼|GE319.78-0.02 (-0.01%) ▼|GEV955.04+3.22 (+0.34%) ▲|GILD149.69-1.68 (-1.11%) ▼|GM80.57-3.20 (-3.82%) ▼|GOOG339.01+4.03 (+1.20%) ▲|GOOGL342.36+4.53 (+1.34%) ▲|GS923.29-13.07 (-1.40%) ▼|HD292.18-4.54 (-1.53%) ▼|HON211.79-0.78 (-0.37%) ▼|IBM227.06-5.70 (-2.45%) ▼|INTC127.39+4.79 (+3.91%) ▲|INTU277.13-9.67 (-3.37%) ▼|ISRG399.52+1.22 (+0.31%) ▲|JNJ270.68+1.51 (+0.56%) ▲|JPM338.56+1.03 (+0.31%) ▲|KO88.10+0.01 (+0.01%) ▲|LIN468.14-1.58 (-0.34%) ▼|LLY1,181.89+30.90 (+2.68%) ▲|LMT523.70-0.98 (-0.19%) ▼|LOW188.49-2.87 (-1.50%) ▼|LRCX307.16-0.12 (-0.04%) ▼|MA566.08+6.16 (+1.10%) ▲|MCD237.02-1.30 (-0.55%) ▼|MDLZ60.86-0.58 (-0.94%) ▼|MDT88.51-0.79 (-0.88%) ▼|META777.59+33.49 (+4.50%) ▲|MMM167.52-2.78 (-1.63%) ▼|MO68.88-0.07 (-0.10%) ▼|MRK147.98-0.10 (-0.07%) ▼|MS196.32-2.07 (-1.04%) ▼|MSFT497.93-2.66 (-0.53%) ▼|MU1,080.53+8.65 (+0.81%) ▲|NEE75.62-1.40 (-1.82%) ▼|NFLX71.72+0.36 (+0.50%) ▲|NKE35.99-0.06 (-0.17%) ▼|NOW137.78-3.00 (-2.13%) ▼|NVDA224.58-0.93 (-0.41%) ▼|ORCL139.54-5.02 (-3.47%) ▼|PEP128.15-2.03 (-1.56%) ▼|PFE28.41+0.23 (+0.82%) ▲|PG145.68-1.71 (-1.16%) ▼|PLTR192.59+0.80 (+0.42%) ▲|PM191.50+0.66 (+0.35%) ▲|QCOM194.26-2.98 (-1.51%) ▼|RTX188.61-3.58 (-1.86%) ▼|SBUX93.65-0.49 (-0.52%) ▼|SCHW99.49-0.01 (-0.01%) ▼|SO82.89-0.58 (-0.69%) ▼|SPG204.70+0.54 (+0.26%) ▲|T25.45+0.15 (+0.59%) ▲|TMO678.39+13.09 (+1.97%) ▲|TMUS165.35-0.31 (-0.19%) ▼|TSLA377.94-2.18 (-0.57%) ▼|TXN270.65-1.97 (-0.72%) ▼|UBER69.22-0.20 (-0.29%) ▼|UNH375.01+3.72 (+1.00%) ▲|UNP274.07-1.46 (-0.53%) ▼|UPS92.05-3.77 (-3.93%) ▼|USB58.40-0.08 (-0.14%) ▼|V367.98+6.46 (+1.79%) ▲|VZ47.32+0.80 (+1.72%) ▲|WFC82.18+0.28 (+0.34%) ▲|WMT107.59-2.94 (-2.66%) ▼|XOM162.14+0.91 (+0.56%) ▲|
18.9 C
New York
Friday, September 25, 2026

Tag: 1

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

Hapbee Reports First-Ever Quarterly Profit in Q2 2025 and Achieves Third Consecutive Quarter of Growth

Strong top-line gains, reduced expenditures, and improved gross margins result in milestone quarter
Strong top-line gains, reduced expenditures, and improved gross margins result in milestone quarter 

Photonic Quantum Computing to Reach US$6.8 Billion by 2035 – PsiQuantum Leads as Photonic Quantum Vendors Rise

Explore the burgeoning world of Photonic Quantum Computers: these cost-effective, room-temperature machines promise significant growth, with revenues projected to soar from $1.1 billion in 2030 to $6.8 billion by 2035. Get insights on key players like PsiQuantum and market forecasts, covering vendors and components in a booming industry.
Explore the burgeoning world of Photonic Quantum Computers: these cost-effective, room-temperature machines promise significant growth, with revenues projected to soar from $1.1 billion in 2030 to $6.8 billion by 2035. Get insights on key players like PsiQuantum and market forecasts, covering vendors and components in a booming industry.

Preservative-Free Eye Drops Market Size to reach US$1.67 billion in 2031 | CAGR of 4.3% | Exclusive Report by The Insight Partners

NEW YORK, July 18, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global preservative-free eye drops market is growing...

Preservative-Free Eye Drops Market Size to reach US$1.67 billion in 2031 | CAGR of 4.3% | Exclusive Report by The Insight Partners

NEW YORK, July 18, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global preservative-free eye drops market is growing...

Vascular Access Devices Company Evaluation Report 2025 | Becton Dickinson, Teleflex, and ICU Medical Strengthen Global Leadership Through Strategic Acquisitions and Product Innovation

The Vascular Access Devices Market Companies Quadrant delivers a thorough analysis of the global vascular access devices sector. Highlighting prominent players, innovations, and trends, it identifies the top 25 companies as quadrant leaders among over 100 evaluated. Vascular access devices (VADs), crucial for treatments like chemotherapy and dialysis, are set to grow from USD 5.99 billion in 2024 to USD 9.05 billion by 2030 at a 7.1% CAGR, fueled by rising demand and investments despite a skilled professional shortage. Key players include Beckton Dickinson, Teleflex, and ICU Medical, known for expanding portfolios through strategic acquisitions and innovations. The quadrant evaluates companies based on revenue, growth strategies, and product footprint across device types and applications.
The Vascular Access Devices Market Companies Quadrant delivers a thorough analysis of the global vascular access devices sector. Highlighting prominent players, innovations, and trends, it identifies the top 25 companies as quadrant leaders among over 100 evaluated. Vascular access devices (VADs), crucial for treatments like chemotherapy and dialysis, are set to grow from USD 5.99 billion in 2024 to USD 9.05 billion by 2030 at a 7.1% CAGR, fueled by rising demand and investments despite a skilled professional shortage. Key players include Beckton Dickinson, Teleflex, and ICU Medical, known for expanding portfolios through strategic acquisitions and innovations. The quadrant evaluates companies based on revenue, growth strategies, and product footprint across device types and applications.

Timbercreek Financial Announces Conference Call to Discuss Second Quarter Financial Results

TORONTO, July 18, 2025 (GLOBE NEWSWIRE) -- Timbercreek Financial (TSX: TF) will hold a conference call and live audio webcast at 1:00 p.m. (ET) on Thursday, July 31, 2025, to discuss financial results for the quarter ended June 30, 2025. The financial results will be released on Wednesday, July 30, 2025, after the markets close. Interested parties are invited to participate in the call with management which will be followed by a question and answer period with analysts.

$1.2 Bn Dry Transformer Insulation Market – Global Forecast to 2030 | Core Insulation to Hold Significant Share, Coatings Segment Emerges as Key Growth...

The dry transformer insulation market is expected to grow from USD 0.93 billion in 2025 to USD 1.21 billion by 2030, demonstrating a CAGR of 5.5%. Key drivers include increased demand for reliable electrical distribution in commercial and residential sectors, urbanization, and infrastructure expansion. Dry transformer insulation solutions are preferred for their low maintenance and eco-friendly attributes, aligning with global energy efficiency and sustainability goals. The Asia Pacific leads the market, fueled by advancements in infrastructure and power initiatives, notably in China and India. However, high coating costs and thermal limitations pose challenges. Top manufacturers like 3M, DuPont, and PPG Industries are pivotal in the market's competitive landscape.
The dry transformer insulation market is expected to grow from USD 0.93 billion in 2025 to USD 1.21 billion by 2030, demonstrating a CAGR of 5.5%. Key drivers include increased demand for reliable electrical distribution in commercial and residential sectors, urbanization, and infrastructure expansion. Dry transformer insulation solutions are preferred for their low maintenance and eco-friendly attributes, aligning with global energy efficiency and sustainability goals. The Asia Pacific leads the market, fueled by advancements in infrastructure and power initiatives, notably in China and India. However, high coating costs and thermal limitations pose challenges. Top manufacturers like 3M, DuPont, and PPG Industries are pivotal in the market's competitive landscape.

Sleep Apnea Devices Market worth $11.6 billion by 2032 with 7.6% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., July 18, 2025 /PRNewswire/ -- The global Sleep Apnea Devices Market, valued at US$6.4 billion in 2024 stood at US$6.9 billion in 2025...

Sleep Apnea Devices Market worth $11.6 billion by 2032 with 7.6% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., July 18, 2025 /PRNewswire/ -- The global Sleep Apnea Devices Market, valued at US$6.4 billion in 2024 stood at US$6.9 billion in 2025...

Technetium-99m Market Size to Reach USD 6.29 Billion by 2031, Growing at a CAGR of 3.9% | Exclusive Report by The Insight Partners

NEW YORK, July 18, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global technetium-99m market is witnessing substantial...

Technetium-99m Market Size to Reach USD 6.29 Billion by 2031, Growing at a CAGR of 3.9% | Exclusive Report by The Insight Partners

NEW YORK, July 18, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global technetium-99m market is witnessing substantial...

Capella Provides Update on Agreement with Tümad Madencilik

www.capellaminerals.com VANCOUVER, BC, July 18, 2025 /CNW/ - Capella Minerals Ltd (TSXV: CMIL) (OTC Pink: CMILF) (FRA: N7D2) ("Capella" or the "Company") is pleased to...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTags1